

17 February 2026

The Company Announcements Office
Australian Securities Exchange
Sydney NSW

Appendix 4D – Half Year Report

1.	Name of Entity	BCAL Diagnostics Limited
		ABN 51 142 051 223
	Half year ended	31 December 2025
	Reporting period	1 July 2025 to 31 December 2025
	Previous period	1 July 2024 to 31 December 2024

2. Results for announcement to the market

	31 December 2025	31 December 2024	% Change Up (Down)
2.1 Revenues from continuing operations	1,272,617	1,385,195	(8%)
2.2 Loss from operations after tax attributable to members	(3,917,411)	(3,999,360)	2%
2.3 Net loss attributable to members	(3,917,411)	(3,999,360)	2%
2.4 Proposed dividends	Nil	Nil	
2.5 Record date for determining dividend	N/A	N/A	
2.6 An explanation of the above figures is contained in the “Review of Operations” included within the attached directors’ report.			

	31 December 2024	31 December 2024	% Change Up (Down)
3. Net tangible asset per security	0.007 cents	0.017 cents	(59%)

4. Details of entities over which control has been gained or lost during the period.

Nil

5. There were no payments of dividends during the reporting period.



6. There is no dividend reinvestment plan in operation.
7. There are no associates or joint venture entities.
8. The Company is not a foreign entity.
9. The accounts are not subject to any audit dispute or qualification.

The Group's half year report follows.

For more information, please contact:

BCAL Diagnostics Limited
Jayne Shaw | Executive Chair
jayneshaw@bcaldiagnostics.com

Mr Guy Robertson | Company Secretary
guyrobertson@bcaldiagnostics.com





INTERIM REPORT

FOR THE HALF-YEAR ENDED
31 DECEMBER 2025

BCAL DIAGNOSTICS LIMITED AND ITS
CONTROLLED ENTITY

ABN 51 142 051 223

Advancing cancer screening
with non-invasive blood tests

For personal use only

CONTENTS

3	●	DIRECTORS' REPORT
5	●	AUDITOR'S INDEPENDENCE DECLARATION
6	●	CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
7	●	CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
8	●	CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
9	●	CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
10	●	NOTES TO THE FINANCIAL STATEMENTS
18	●	DIRECTORS' DECLARATION
19	●	INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS

DIRECTORS' REPORT

The directors' of BCAL Diagnostics Limited ("the Company") and its controlled entity ("BCAL" or "Group") present their report, together with the financial statements, for the half-year ended 31 December 2025.

DIRECTORS

The following persons were directors of the Company during the whole of the half-year and up to the date of this report, unless otherwise stated:

Jayne Shaw	Executive Chair
Jonathan Trollip	Non-executive Director
David Darling	Non-executive Director
John Hurrell	Non-executive Director
Mark McConnell	Non-executive Director, appointed 1 February 2026
Ronald Phillips	Non-executive Director, resigned 28 August 2025
Mark Burrows	Non-executive Director, resigned 28 August 2025

PRINCIPAL ACTIVITIES

During the half-year period the principal continuing activities of the Group consisted of continuing research into the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer including preparation for clinical trials, and expanding its portfolio into the early detection of multiple cancers through the collaboration with ClearNote Health.

REVIEW OF OPERATIONS

The loss for the financial half-year ended 31 December 2025, after tax, amounted to \$3,917,411 (2024: loss \$3,999,360).

The results reflect early revenues from the commercialisation of BREASTEST plus™, expenditure on ongoing investment in commercialisation activities, clinical engagement, research and development, and corporate overheads for the period.

BCAL continued the staged commercial rollout of its first product, BREASTEST plus™, a non-invasive blood-based diagnostic test designed to support clinical evaluation of breast disease in women with dense breast tissue. BCAL expanded patient access through a strategic collaboration with Sonic Healthcare, formalising collection services at 90 pathology centres in Sydney, providing access close to home. This arrangement provides clinicians and patients with broader convenience and faster test turnaround. BCAL's rollout remains focused on metropolitan centres initially, with further expansion planned.

BCAL also entered into various partnerships, to support clinical engagement and distribution of BREASTEST plus™ across additional regions including one site in Coffs Harbour and two collection sites in Brisbane.

During the period, BCAL secured an exclusive licence agreement with ClearNote Health, Inc. to commercialise advanced epigenomics-based cancer detection tests for pancreatic and ovarian cancer in Australia and New Zealand. These tests, Avantect® Pancreatic and Avantect® Ovarian commenced rollout in Australia in January 2026, expanding BCAL's diagnostic portfolio beyond breast cancer into additional high-impact oncology indications. Nationwide access will be supported through BCAL's partnerships with ClearNote and Sonic Healthcare's pathology network, enabling clinicians to access the tests and enhancing early detection pathways for patients.

The licence arrangement is an important strategic milestone, building on ClearNote's international clinical and regulatory progress and positioning BCAL to deliver a broader suite of early detection tools for cancers that traditionally have limited early-stage diagnostic options.

BCAL established a \$10 million Convertible Note facility to strengthen working capital and support its commercial and product development objectives. The facility includes firm commitments for initial funding of circa \$5 million with an option to expand the facility to the full amount, and includes conversion rights into ordinary shares as part of BCAL's broader capital strategy.

As at 31 December 2025, BCAL held cash and cash equivalents of \$3.3 million (30 June 2025: \$4.5 million), providing funding to support near-term operational priorities. The Directors continue to actively manage the Company's cash position and capital resources to support key clinical, commercial and regulatory milestones.

BCAL's near-term focus is on expanding access to BREASTEST plus™ in additional metropolitan and regional centres, progressing the Australian launch of the Avantect® pancreatic and ovarian cancer tests, strengthening clinical and pathology engagement, and supporting broader clinician adoption of its diagnostic platforms.

On 26 November 2025, BCAL confirmed the receipt of its FY2025 Research and Development Tax Incentive (RDTI) tax offset in the amount of \$2.5M. The tax offset is a critical aspect to BCAL funding the development of BREASTEST® and the Company values the strong government support in progressing the commercialisation of breast cancer diagnostic tools like BREASTEST®. The RDTI is an Australian Government program providing important support for biotechnology and other sectors under which companies receive a refund for eligible expenditure on research and development.

ROUNDING OF AMOUNTS

In accordance with ASIC Corporations (Rounding in Financial/Director's Reports) Instrument 2016/191, the amounts in the directors' report and in the financial report have been rounded to the nearest dollar, unless otherwise stated.

AUDITOR'S INDEPENDENCE

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 5.

Signed in accordance with a resolution of the directors.



Jayne Shaw

Executive Chair

17 February 2026

**Auditor's Independence Declaration
To the Directors of BCAL Diagnostics Limited
ABN 51 142 051 223**

In relation to the independent auditor's review of BCAL Diagnostics Limited and its controlled entity for the half year ended 31 December 2025, to the best of my knowledge and belief there have been:

- (i) no contraventions of the auditor independence requirements of the *Corporations Act 2001*; and
- (ii) no contraventions of APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)*.

This declaration is in respect of BCAL Diagnostics Limited and the entity it controlled during the period.

**Rod Shanley**
Partner**Pitcher Partners**
Sydney

17 February 2026

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	NOTE	HALF-YEAR ENDED 31 DECEMBER 2025	HALF-YEAR ENDED 31 DECEMBER 2024
		\$	\$
REVENUE FROM CONTINUING OPERATIONS			
Income	3	1,272,617	1,385,195
EXPENSES			
Research and development		(2,520,148)	(2,127,099)
Personnel costs		(226,839)	(140,822)
Marketing		(243,611)	(68,688)
Consulting fees		(286,052)	(357,670)
Directors' fees		(198,520)	(200,702)
Regulatory expenses		(103,118)	(144,825)
General and administration		(766,862)	(700,001)
Depreciation		(391,863)	(615,707)
Facilities costs		(130,190)	(481,110)
Interest expense		(107,172)	(48,751)
Share based payments	4	(194,354)	(499,180)
Loss before income tax		(3,896,112)	(3,999,360)
Income tax		(21,299)	-
Net loss after income tax		(3,917,411)	(3,999,360)
Other comprehensive income for the year		-	-
Total comprehensive loss for the year		(3,917,411)	(3,999,360)
Loss is attributable to:			
Members of BCAL Diagnostics Limited		(3,917,411)	(3,999,360)
EARNINGS PER SHARE			
From continuing operations		Cents	Cents
- Basic loss per share		(1.07)	(1.09)
- Diluted loss per share		(1.07)	(1.09)

The above Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 DECEMBER 2025

	NOTE	31 DECEMBER 2025 \$	30 JUNE 2025 \$
ASSETS			
Current Assets			
Cash and cash equivalents		3,330,917	4,522,756
Tax receivables		1,344,582	2,584,026
Other receivables and prepayments		104,858	88,472
Total Current Assets		4,780,357	7,195,254
Non-Current Assets			
Plant and equipment		1,898,407	2,109,705
Right of use assets		494,157	603,970
Total Non-Current Assets		2,392,564	2,713,675
Total Assets		7,172,921	9,908,929
LIABILITIES			
Current Liabilities			
Trade and other payables		737,842	1,197,070
Borrowings	5	229,022	1,575,381
Lease liability		235,329	223,171
Provisions		99,952	111,999
Total Current Liabilities		1,302,145	3,107,621
Non-Current Liabilities			
Borrowings	5	2,639,027	122,148
Derivative liability	5	397,240	-
Lease liability		336,649	458,243
Total Non-Current Liabilities		3,372,916	580,391
Total Liabilities		4,675,061	3,688,012
Net Assets		2,497,860	6,220,917
EQUITY			
Contributed equity	6	33,950,596	33,834,690
Reserves		545,960	467,512
Accumulated losses		(31,998,696)	(28,081,285)
Equity		2,497,860	6,220,917

The above Statement of Financial Position should be read in conjunction with the accompanying notes.

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

2025	CONTRIBUTED EQUITY	RESERVES	ACCUMULATED LOSSES	TOTAL
	\$	\$	\$	\$
At 1 July 2025	33,834,690	467,512	(28,081,285)	6,220,917
Loss for the period	-	-	(3,917,411)	(3,917,411)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the half year	-	-	(3,917,411)	(3,917,411)
Transaction with owners in their capacity as owners				
Transfer from reserves	115,906	(115,906)	-	-
Share based payments	-	194,354	-	194,354
At 31 December 2025	33,950,596	545,960	(31,998,696)	2,497,860
At 1 July 2024	28,895,408	668,978	(20,975,961)	8,588,425
Loss for the period	-	-	(3,999,360)	(3,999,360)
Other comprehensive income	-	-	-	-
Total comprehensive loss for the half year	-	-	(3,999,360)	(3,999,360)
Transactions with owners in their capacity as owners				
Share issue	4,765,000	-	-	4,765,000
Share issue costs	(168,100)	-	-	(168,100)
Transfer from reserves	344,289	(480,000)	135,711	-
Share based payments	-	84,180	-	84,180
At 31 December 2024	33,836,597	273,158	(24,839,610)	9,270,145

The above Condensed Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

	NOTE	HALF-YEAR ENDED 31 DECEMBER 2025	HALF-YEAR ENDED 31 DECEMBER 2024
		\$	\$
CASH FLOWS FROM OPERATING ACTIVITIES			
Payments to suppliers and employees		(4,865,656)	(5,331,689)
Research and development tax offset received		2,469,717	2,628,703
Interest paid		(123,939)	(49,736)
Interest received		24,072	81,063
Net cash outflow from operating activities		(2,495,806)	(2,671,659)
CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of plant and equipment		(452,356)	(741,851)
Proceeds on sale of plant and equipment		301,763	-
Net cash outflow from investing activities		(150,593)	(741,851)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from share issue	6	-	4,300,000
Costs of share issue		-	(113,100)
Proceeds from convertible note		3,000,000	-
Repayment of borrowings		(1,436,003)	(122,211)
Principal element of lease payments		(109,437)	(112,091)
Net cash inflow from financing activities		1,454,560	3,952,598
Net (decrease)/increase in cash and cash equivalents		(1,191,839)	539,088
Cash and cash equivalents at the beginning of the period		4,522,756	6,472,988
Cash and cash equivalents at end of the period		3,330,917	7,012,076

The above Condensed Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.

NOTES TO THE FINANCIAL STATEMENTS

FOR THE HALF-YEAR ENDED 31 DECEMBER 2025

NOTE 1. SUMMARY OF MATERIAL ACCOUNTING POLICIES

(a) Basis of preparation

These consolidated financial statements for the interim half-year reporting period ended 31 December 2025 have been prepared in accordance with the requirements of the Corporations Act 2001 and Australian Accounting Standard AASB 134 Interim Financial Reporting, as appropriate for for-profit entities. Compliance with Australian Accounting Standards 134 ensures that the financial statements and notes comply with International Financial Reporting Standards IAS 34 'Interim Financial Reporting'.

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

The interim financial report is intended to provide users with an update on the latest annual financial statements of the Group as at 31 December 2025. As such it does not include all the notes of the type normally included in an annual report. Accordingly, this report should be read in conjunction with the annual report for the year ended 30 June 2025 and any public announcements made during the interim reporting period.

The accounting policies and methods of computation have been consistently followed in this interim financial report as were applied in the previous annual financial statements for the year ended 30 June 2025, with the exception of that relating to the convertible note (See Note 5).

Rounding of amounts

In accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, the amounts in this report have been rounded to the nearest dollar unless otherwise stated.

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company as at 31 December 2025 and the results of all subsidiaries for the period then ended. BCAL Diagnostics Limited and its subsidiary together are referred to in these financial statements as the 'BCAL' or 'the Group'.

Corporate Information

BCAL Diagnostics Limited is an ASX listed company limited by shares, incorporated and domiciled in Australia. The consolidated financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standard Board and the Corporations Act 2001.

Compliance with Australian Accounting Standards ensures that the financial statements and notes also comply with International Financial Reporting Standards. Material accounting policies adopted in the preparation of this financial report are presented below. They have been consistently applied unless otherwise stated.

In accordance with ASIC Corporations (Rounding in Financial/Directors' Reports) Instrument 2016/191, the amounts in the directors' report and in the financial report have been rounded to the nearest dollar, unless otherwise stated.

The financial report has been prepared on an accruals basis and is based on historical costs, except for selected financial assets for which the fair value basis of accounting has been applied.

Corporate Head Office
Suite 506, Level 5, 50 Clarence Street, Sydney NSW 2000.
Principal Place of Business
Level 2, 11 Julius Avenue North Ryde NSW 2113

(b) Going concern

The financial statements have been prepared on a going concern basis which contemplates the realisation of assets and the settlement of liabilities in the normal course of business.

As disclosed in the financial statements, the Group incurred losses of \$3,917,411, had net cash outflows from operating activities of \$2,495,806 and net cash outflows from investing activities of \$150,953, for the half-year ended 31 December 2025. Based on current projections, the current commitment under the convertible note facility together with the research and development tax offset and product revenues, will see the Group through to early calendar year 2027.

The Directors believe that it is reasonably foreseeable that the Group will continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following factors:

- The Group had \$3,330,917 in cash on hand at 31 December 2025;
- The Group has put in place a convertible note facility of \$10 million, on which it has drawn \$3 million, has firm commitments for a further \$2 million, and has parties that are interested in participating in the remaining \$5 million of the facility;
- The Group has demonstrated ability to raise capital and has the ability to raise capital if required in the future;
- The Group will have a Research and Development Offset claim in respect of the current financial year, and has the ability to fund this claim, if required; and
- The Group has the ability to slow activity and reduce costs should this be required.

On this basis no adjustments have been made to the financial report relating to the recoverability and classification of the carrying amount of assets or the amount and classification of liabilities that might be necessary should the Group not continue as a going concern. Accordingly, the financial report has been prepared on a going concern basis.

Should the Group be unsuccessful with the initiatives detailed above then, there is a material uncertainty that may cast significant doubt as to whether the Group may in the future be able to continue as a going concern and may therefore be required to realise assets and extinguish liabilities other than in the ordinary course of business with the amount realised being different from those shown in the financial statements.

(c) Critical accounting estimates and judgements

There have been no significant changes to the critical accounting estimates and judgements applied and disclosed in the annual report for the year ended 30 June 2025.

(d) New and revised accounting requirements applicable to the current half- year reporting period

There are no new accounting standards or interpretations applicable that would have a material impact on the accounts of the Group.

NOTE 2. SEGMENT INFORMATION

BCAL Diagnostics Limited is an Australian company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost effective, accurate and available to all women regardless of age, race and geographic location. The Group has expanded its product offering to include multi cancer early detection tests, including for ovarian and pancreatic cancer.

The Group incorporated a US subsidiary, BCAL Diagnostics, Inc. on 30 July 2024, which became operational on 2 September 2024. This entity performs activities analogous to Australia, and the Group is therefore considered to be in one business segment.

NOTE 3. INCOME

	HALF-YEAR ENDED 31 DECEMBER 2025	HALF-YEAR ENDED 31 DECEMBER 2024
	\$	\$
Product sales	42,618	-
Research and development tax offset	1,202,113	1,149,549
Research and development tax offset, prior period adjustment	-	128,703
Interest income	24,072	106,943
Other income	3,814	-
	1,272,617	1,385,195

NOTE 4. SHARE BASED PAYMENTS

	HALF-YEAR ENDED 31 DECEMBER 2025	HALF-YEAR ENDED 31 DECEMBER 2024
	\$	\$
Shares issued to Directors	-	315,000
Performance rights (refer to Note 6 (c))	194,354	84,180
Shares issued for services rendered	-	100,000
	194,354	499,180

NOTE 5. BORROWINGS

	31 DECEMBER 2025	30 JUNE 2025
	\$	\$
CURRENT		
Short term loan		
Opening balance	1,302,536	-
Short term loan (repayment)/advance	(1,302,536)	1,302,536
	-	1,302,536
Equipment financing	229,022	272,845
	229,022	1,575,381
NON-CURRENT		
Financial liability – Convertible Notes	2,602,760	-
Equipment finance liability	36,267	122,148
Borrowings	2,639,027	122,148
Derivative liability		
Fair value of embedded derivative	397,240	-

The Group issued 5,000,000 unsecured, partly paid convertible notes drawn to \$3,000,000 on 17 December 2025. The notes are convertible into ordinary shares of the Company, at the option of the holder, at a price in the first year at a discount of 20% to the 28 day VWAP prior to conversion, and in the second year at a discount of 25% to the 28 day VWAP prior to conversion, provided that the minimum price will not be less than \$0.096 and will not be greater than \$0.30.

Interest on the outstanding value of the notes will accrue at 10% per annum and unpaid interest at 30 June in each year will be added to the capital amount and be subject to interest.

The notes were issued to fund general working capital.

The Convertible Notes have been valued by determining 1) The fair values of the conversion options of the Convertible Notes using a Monte Carlo Simulation Approach; and 2) the value of the host debt contract with respect to market rates of return by deducting from the face value of the Notes the amount determined in 1.

Embedded Derivatives

Embedded within the convertible notes are derivatives relating to the exchange rights and redemption rights of the notes. The initial fair value of the embedded derivatives have been estimated using Monte Carlo option pricing models with subsequent fair value movements to be recognised in profit and loss.

NOTE 6. CONTRIBUTED EQUITY**(a) Share capital**

	31 DECEMBER 2025	31 DECEMBER 2025	30 JUNE 2025	30 JUNE 2025
	# SHARES	\$	# SHARES	\$
Ordinary Shares - Fully Paid	368,067,640	33,950,596	365,967,890	33,834,690

Movements in ordinary shares

	DATE	NUMBER OF SHARES	ISSUE PRICE	\$
Opening balance 1 July 2024		314,294,714		28,895,408
Issue of shares, placement	23/7/2024	43,000,000	\$0.10	4,300,000
Issue of shares to directors	18/12/2024	3,000,000	\$0.11	315,000
Issue of shares, services performed	16/09/2024	869,565	\$0.12	100,000
Issue of shares, services performed	9/8/2024	500,000	\$0.10	50,000
Issue of shares, conversion of performance rights	18/12/2024	4,303,611	\$0.08	344,289
Cost of issue of shares		-		(170,007)
Closing balance 30 June 2025		365,967,890		33,834,690
Issue of shares, conversion of performance rights	27/10/2025 & 12/12/2025	2,099,750	\$0.06	115,906
		368,067,640		33,950,596

(b) Options

	NUMBER OF OPTIONS	ISSUE DATE	DATE OF EXPIRY	EXERCISE PRICE (\$)
Employee options	3,467,353	20/11/2019	20/11/2029	\$0.06
Broker/adviser options	1,034,243	17/10/2023	17/10/2026	\$0.20
Director options	12,000,000	18/12/2024	8/10/2027	\$0.25
Total	16,501,596			

The vesting of employee options is subject to employee service periods. All of the options on issue have vested, with the exception of the Director options which will vest over two years from the issue date.

Movements in Options

No options have been issued or exercised during the period.

(c) Performance rights

The Group recognised share-based payment expenses of \$194,354 in relation to performance rights for the half-year (2024: \$84,180). No performance rights were issued in the current period.

The Group issued 9,150,000 performance rights to employees during the half year ended 31 December 2024. A reconciliation of performance rights issued, vested and lapsed is as follows:

PERFORMANCE RIGHTS	
Opening balance 1 July 2024	6,082,856
Performance rights issued	9,150,000
Performance rights converted to shares	(4,303,611)
Performance rights lapsed	(1,779,245)
Closing balance 30 June 2025	9,150,000
Performance rights converted to shares	(2,099,750)
Closing balance 31 December 2025	7,050,250

The Company has issued performance rights subject to performance conditions aligned with annual strategic milestones for the years ended 30 June 2025, 2026 and 2027. Subsequent to the end of each financial year, performance is measured and subject to discretion of the Board the performance rights vest or lapse. Performance rights do not vest unless the employee is employed at the end of the performance measurement period.

The entity measures the cost of employee performance rights by reference to the fair value of the performance rights at the date at which they are granted. The fair value is determined by using the Black-Scholes model taking into account the terms and conditions upon which the rights are granted. The expense is recognised over the relevant performance period (usually a financial year) commencing at or around the time that the strategic milestone was agreed and communicated to the holder of the performance rights, adjusted for a probability that the milestone will be satisfied. There are no market based performance conditions.

Performance rights vested during the period, relating to the 2024/2025 financial years, were converted to 2,099,750 ordinary shares on 27 October 2025 and 15 December 2025. The share price at the time of conversion was 8 cents and 10 cents per share respectively.

Performance rights expire on 31 December 2027 have a Nil exercise price and a fair value of 9.2 cents. No amount is payable on the exercise of performance rights. The performance rights hurdles are based on successful product launches, achieving revenue targets, profitability and efficient laboratory operations. The overall probability of all team members achieving the milestones has been set at 60%.

The 2023/2024 performance rights expired on 30 September 2024 have a Nil exercise price and a fair value between 8 cents and 10 cents. No amount is payable on the exercise of performance rights. The performance rights hurdle for that period was based on progress made towards commercialising a product in line with the timing set out in the business plan, and was set at a probability of 80%. The remaining 2023/2024 performance rights, 1,779,245, were lapsed in the prior year.

NOTE 7. FAIR VALUE MEASUREMENT

The net value of current assets and liabilities approximates their carrying value, due to their short-term nature. The aggregate net fair values and carrying amounts of financial assets and financial liabilities are disclosed in the Statement of Financial Position and in note 5 to the financial statements.

a) Fair value hierarchy

The following tables detail the consolidated entity's assets and liabilities, measured or disclosed at fair value, using a three-level hierarchy, based on the lowest level of input that is significant to the entire fair value measurement, being:

- *Level 1*: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date
- *Level 2*: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly
- *Level 3*: Unobservable inputs for the asset or liability

	LEVEL 1	LEVEL 2	LEVEL 3
	\$	\$	\$
As at 31 December 2025			
Financial liabilities measured at fair value:			
Derivative financial instruments – convertible option on convertible notes	-	-	397,240

b) Level 3 assets and liabilities

Movements in level 3 assets and liabilities during the current and previous financial year are set out below:

	DERIVATIVE
	\$
Balance as at 30 June 2025	-
Additions	397,240
Balance as at 31 December 2025	397,240

c) Valuation technique and inputs of convertible notes

The fair value of the embedded derivative is recognised using the Monte Carlo option pricing model ("Monte Carlo Model"). The following assumptions were used in the Monte Carlo Model:

	YEAR ENDED 31 DECEMBER 2025
Share price	\$0.11
Exercise price	\$0.20
Risk-free interest rate	4.06%
Equity conversion rate	50%
Interest rate on convertible debenture	10%
Expected dividend yield	Nil
Estimated common share price volatility	73%
Estimated life in years	2

(d) Sensitivity analysis of convertible notes

Volatility is a key input to the Monte Carlo model and involves a significant degree of estimation uncertainty. Management has performed sensitivity analysis by recalculating the valuation using alternative volatility assumptions within a reasonably possible range. While the valuation outcomes vary in response to changes in volatility, the base-case valuation is considered representative of fair value.

NOTE 8. COMMITMENTS

There were no commitments as at 31 December 2025 (31 December 2024: Nil).

NOTE 9. CONTINGENCIES

The Group did not have any contingent assets or liabilities at 31 December 2025 (31 December 2024: Nil).

NOTE 10. EVENTS SUBSEQUENT TO BALANCE DATE

There are no matters or circumstances that have arisen since the end of the financial period that have significantly affected or may significantly affect the operations of the Group, the results of those operations, or state of affairs of the Group in future financial years.

NOTE 11. DIVIDENDS

There were no dividends paid, recommended or declared during the current or previous reporting period.

DIRECTORS' DECLARATION

THE DIRECTORS OF THE COMPANY DECLARE THAT:

1. In the directors opinion, the financial statements and notes thereto, as set out on pages 6 to 17, are in accordance with the Corporations Act 2001, including:
 - (a) complying with Australian Accounting Standard 134 Interim Financial Reporting and the Corporations Regulations 2001; and
 - (b) giving a true and fair view of the Group's financial position as at 31 December 2025 and performance for the half-year ended on that date; and
2. As disclosed in Note 1(b), in the directors' opinion there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Jayne Shaw

Executive Chair

17 February 2026

**Independent Auditor's Review Report
To the Members of BCAL Diagnostics Limited
ABN 51 142 051 223****Report on the Half-Year Financial Report****Conclusion**

We have reviewed the half-year financial report of BCAL Diagnostics Limited ("the Company") and its controlled entity ("the Group"), which comprises the condensed consolidated statement of financial position as at 31 December 2025, the condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the half-year ended on that date, a summary of material accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the Group does not comply with the *Corporations Act 2001* including:

- a) giving a true and fair view of the Group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- b) complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the Group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* ("the Code") that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We confirm that the independence declaration required by the *Corporations Act 2001* which has been given to the directors of the Group, would be in the same terms if given to the directors as at the time of this auditor's review report.

Material Uncertainty Related to Going Concern

We draw attention to Note 1(c) in the financial report, which indicates that the Group incurred a net loss of \$3,917,411 during the half-year ended 31 December 2025 and that, based on current projections, the Group will need to raise additional funds. As stated in Note 1(c), these events or conditions, along with the other matters as set forth in Note 1(c), indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Responsibility of the Directors for the Financial Report

The directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility for the Review of the Financial Report

Our responsibility is to express a conclusion on the half-year financial report based on our review. ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Rod Shanley
Partner



Pitcher Partners
Sydney

17 February 2026

For personal use only



BCAL Diagnostics Limited
Suite 506 Level 5
50 Clarence Street
Sydney NSW 2000